Y2023
Licensed out AL101-AMD for wet AMD to Hanlim Pharm

Y2022
Completed Phase 2a clinical trial for AL101-MASH
Completed Phase 2 clinical trial for AL101-AMD
Completed Phase 2 clinical trial for AL102-PDT

Y2019 ~ Y2021
V.C. funding 8.5 billion KRW

Y2019
Signed a MOU on PASylation technology with XL-protein
Received the Korea Industry Grand Prize in Biotechnology Award from Money Today
Received the Korea KONEX Award for Best Technology by the Korea Exchange

Y2018
Launched sales of Ob-X on home-shopping channels

Y2016
Listed in KONEX

Y2013 ~ Y2016
V.C. funding 12 billion KRW

Y2015
AL101-AMD Phase 2 IND approved

Y2012
Started sales of Ob-X in Korea and overseas

Y2010
Ob-X approved as a functional ingredient with health claim by MFDS

Y2009
Completed Phase 2 clinical trial of AL101-AOB for abdominal obesity

Y2007
Awarded INNO-BIZ certification by the SMBA (Small and Medium Business Administration)

Y2006
Attracted capital from the KDB (Korea Development Bank) for technology development

Y2005
Selected as an 'Excellent Company' by the Korea Technology and Credit Guarantee Agency

Y2004 ~ Y2009
Awarded numerous research grants from the Ministry of Health & Welfare and the SMBA for developing new drugs

Y2000
Research center was certified

Y1999
Recognized as a start-up with good technology